ScienceStudy: New breeding methods hardly contribute to climate protectionAccording to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050. more ➔
vaccinesCEPI commits up to US$80m to University of Oxford to develop vaccinesThe Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against … more ➔
Agri-biotechPairwise and Bayer collaborate to CRISPR short-stem maizeBayer and Pairwise extend their collaboration in precision breeding for five further years to develop CRISPR applications for Bayer’s Preceon Smart Corn System. more ➔
FinancingMystery solved: Mysthera Theapeutics launches with $3.5mMysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune … more ➔
financingMithra raises €20m through private placementWomen’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise €20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice … more ➔
AMRDutch researchers and Novobiotics Inc present weapon vs AMRResearchers at the Universities of Bonn (Germany) and Utrecht (The Netherlands and from NovoBiotic Pharmaceuticals (Cambridge, US) have discovered a new class of antibiotics. They isolated clovibactin … more ➔
BiomanufacturingUK invests in biopharma manufacturers The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life … more ➔
OphtalmologySynbio experts develop cells that hearETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music. more ➔
CollaborationOxford Biomedica expands agreement with Cabaletta Bio British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally … more ➔
MicrobiologyResearchers decipher mystery of oil-eating microbesOil-eating bacteria form dendritic biofilms that reshape oil droplets to speed up the rate of consumption more ➔
